{'fraction_non_alphanumeric': 0.035486160397444996, 'fraction_numerical': 0.019694819020581972, 'mean_word_length': 4.817337461300309, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Case Series on the Heightened Autonomic Response due to Guanfacine and Amphetamine Interaction

Guanfacine is used clinically as either monotherapy or adjunct therapy (along with psychostimulants) for the treatment of attention deficit hyperactivity disorder (ADHD) due to its hypothesized action of increasing network connections in the prefrontal cortex (1). Guanfacine is a selective α2A-adrenoreceptor (α2A-receptor) agonist that activates central nervous system (CNS) norepinephrine receptors in the locus coeruleus. This action results in reduced peripheral sympathetic tone of both systolic (SBP) and diastolic blood pressure (DBP), which was its original indication as an antihypertensive (2). Additionally, guanfacine has been investigated for the treatment of substance abuse disorders (SUD) due to its ability to decrease both stress and cue induced craving (3). Dextroamphetamine (AMP) is a monoamine agonist that blocks neurotransmitter reuptake at the presynaptic transporter and is also taken up by the vesicular monoamine transporter 2, resulting in catecholamine release and CNS stimulation (4). AMP is a well-established therapy for ADHD; however, it also has a propensity to be abused due to its similarity to drugs of abuse such as cocaine and methamphetamine (5) and its cognitive enhancing properties. 
 
As part of a larger study, nine otherwise healthy nicotine dependent volunteers were recruited to take part in a positron emission tomography (PET) protocol examining the effects of oral guanfacine on dopamine release. All subjects were required to stop smoking by midnight the night before all scans, which was verified by carbon monoxide levels less than 10 ppm. Subjects were imaged at baseline (under no pharmacological intervention) and after an oral AMP challenge to assess pre-guanfacine treatment dopamine release the following day. As part of the PET scanning procedure, vital sign measurements were taken twice at baseline and then every 15 minutes after being administered AMP for the duration of the 180-minute scans, which were averaged to reduce potential variability for the purpose of this case series. After pre-treatment scans were complete, subjects took part in a guanfacine escalation paradigm to 3mg daily over fifteen days then remained on a steady state of 3mg guanfacine for eight additional days. To confirm medication compliance, a riboflavin marker detectable in urine by ultraviolet light was added to each dose. After the three weeks of guanfacine monotherapy, subjects took part in a post-guanfacine treatment baseline scan accompanied by a fourth and final scan using the same AMP challenge to examine the effects of chronic guanfacine treatment on dopamine release. 
 
All nine subjects completed the pre-AMP challenge baseline scans without incident and remained normotensive throughout scanning sessions evidenced by an average SBP of 129 mmHg, an average DBP of 75 mmHg, and an average heart rate (HR) of 73 bpm. The first two subjects in the study received 0.5mg/kg (mean of 40mg per dose) of AMP for their pre-guanfacine treatment dopamine release scans without incident and experienced expected autonomic nervous system (ANS) changes as SBP increased by 14% (mean of 151 mmHg), DBP increased by 12% (mean of 76 mmHg), and HR increased by 10% (mean of 80 bpm) over the session as compared to pre-AMP baseline. After the three weeks of guanfacine montherapy, the same two subjects were scanned before a second AMP challenge and, as expected, decreases in ANS measures were observed as compared to their pre-guanfacine baseline scans. Specifically, there was a 13% decrease in SBP (mean of 114 mmHg), a 1% increase in DBP (mean of 69 mmHg), and a 19% decrease in HR (mean of 59 bpm), respectively. Surprisingly however, after receiving 0.5mg/kg of AMP after three weeks of guanfacine monotherapy, those two subjects became acutely stage II hypertensive as reflected by a 50% increase in SBP (mean of 170 mmHg), a 42% increase in DBP (mean of 97 mmHg), and a 1% decrease in HR (mean of 59 bpm). Subjects were asymptomatic with the exception of a mild to moderate headache that subsided without intervention in one of the subjects (See Figure 1). 
 
 
 
Figure 1 
 
Relative change between guanfacine and guanfacine + dextroamphetamine (AMP) (along with S.E.M) in systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR). AMP was given as two different single doses. 
 
 
 
Doses of AMP were then adjusted to 0.4mg/kg in order to safely complete the study on the seven additional subjects (mean of 31mg per dose) and, again, an expected autonomic response was observed during their pre-guanfacine treatment dopamine release scan as AMP increased SBP by 16% (mean of 148 mmHg) and DBP by 9% (mean of 83 mmHg), and decreased HR by 5% (mean of 69 bpm) as compared to their pre-AMP baseline scans. After the three weeks of guanfacine monotherapy, the seven subjects were scanned before their second AMP challenge and deceases in SBP of .1% (mean of 127 mmHg), DBP of 9% (mean of 71 mmHg), and HR of 8% (mean of 65 bpm) were observed as compared to their pre-AMP baseline. Those same subjects experienced asymptomatic acute stage I hypertension (rather than stage II hypertension previously observed with 0.5mg/kg in the prior two subjects) after receiving 0.4mg/kg of AMP. Although autonomic changes were still observed, they were of more benign nature evidenced by a 24% increase in SBP (mean of 156 mmHg), a 23% increase in DBP (mean of 87 mmHg), and a 1% increase in HR (mean of 65 bpm) as compared the post-guanfacine baseline scan (See Figure 1).